Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The launch of the study was on the occasion of the International Day of Persons with Disabilities
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
The proposed transaction will be effected as a share swap
Winlevi is authorized in EU for the treatment of acne vulgaris
The move is expected to be crucial during health crises
Relmada expects to initiate its Phase 3 program in the first half of 2026
Subscribe To Our Newsletter & Stay Updated
